Evidence map›Paper›PMID 41045933›Full record

ArticleCell reports. Medicine2025

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Yuxiang Ma, Shaoyan Lin, Qun Chen, Jinhui Xue, Yunpeng Yang, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen and 21 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Yuxiang MaDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China.
Shaoyan LinDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China.
Qun ChenDepartment of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou 350000, China.
Jinhui XueDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China.
Yunpeng YangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China.
Aimin ZangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
Ying ChengDepartment of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China.
Yiping ZhangThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China.
Xiangcai WangDepartment of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou 341001, China.
Zhendong ChenDepartment of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230093, China.
Song QuDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Cancer Institute of Guangxi, Nanning 530021, Guangxi, China.
Jianbo HeDepartment of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital, Cancer Institute of Guangxi, Nanning 530021, Guangxi, China.
Chuanben ChenDepartment of Head and Neck Radiation Oncology, Fujian Cancer Hospital, Fuzhou 350000, China.
Chuan JinDepartment of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China.
Dongyuan ZhuRare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Qingshan LiDepartment of Oncology, Affiliated Hospital of Chengde Medical University, Chengde 067000, China.
Xianling LiuDepartment of Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Wuyun SuDepartment of Medical Oncology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China.
Yi BaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Weiwei LiDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Xiamen 361027, China.
Qian LiDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Xiamen 361027, China.
Changbin ZhuDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Xiamen 361027, China.
Zhan HuangDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Xiamen 361027, China.
Xiaoyan KangClinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan 250000, China.
Shilin XueClinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan 250000, China.
Hui LiClinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan 250000, China.
Chao WangClinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan 250000, China.
Fan LuoDepartment of Intensive Care Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China.
Yan HuangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China. Electronic address: huangyan@sysucc.org.cn.
Li ZhangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China. Electronic address: zhangli@sysucc.org.cn.
Hongyun ZhaoDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, No. 651 Dongfeng East Road, Guangzhou 510060, China. Electronic address: zhaohy@sysucc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

QL1706 has shown promising efficacy in solid tumors in a phase 1/1b study. Here, we report updated long-term survival outcomes and biomarker analyses. Among 468 patients treated with QL1706 (5 mg/kg), median progression-free survival (mPFS) and overall survival (mOS) are 1.5 and 14.2 months for non-small cell lung cancer (NSCLC), 1.9 and 20.2 months for nasopharyngeal carcinoma (NPC), and 4.2 and 18.6 months for cervical cancer (CC), respectively. Liver metastasis is correlated with poor progression-free survival (PFS) and overall survival (OS) in NSCLC and poor OS in CC, while elevated lactate dehydrogenase is linked to shorter PFS and OS in NPC. CDK4/11q13 diploid or the expression of GZMK

Indexed as

Biomarkers, TumorCTLA-4 AntigenImmune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 ReceptorAdultAgedCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsProgression-Free SurvivalBiomarkers, TumorCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorbifunctional PD-1biomarkercervical cancerCTLA-4 antibodynasopharyngeal carcinomanon-small cell lung cancerphase 1 trial

Identifiers

PMID41045933
PMCPMC12629821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.